MX2023012527A - Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea. - Google Patents
Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea.Info
- Publication number
- MX2023012527A MX2023012527A MX2023012527A MX2023012527A MX2023012527A MX 2023012527 A MX2023012527 A MX 2023012527A MX 2023012527 A MX2023012527 A MX 2023012527A MX 2023012527 A MX2023012527 A MX 2023012527A MX 2023012527 A MX2023012527 A MX 2023012527A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- dimorpholin
- triazin
- piperidin
- dimethylamino
- Prior art date
Links
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000013011 aqueous formulation Substances 0.000 title abstract 2
- 150000007524 organic acids Chemical class 0.000 abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 2
- 150000007522 mineralic acids Chemical class 0.000 abstract 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 abstract 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 abstract 1
- -1 inorganic acid salt Chemical class 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una formulación acuosa farmacéutica que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]c arbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil ]urea, o una sal de ácido orgánico o inorgánico aceptable desde el punto de vista farmacéutico de esta, un ácido orgánico o inorgánico aceptable desde el punto de vista farmacéutico, una beta o gamma-ciclodextrina aceptable desde el punto de vista farmacéutico y agua, que es una solución transparente, siempre que el ácido orgánico o inorgánico (inclusive una sal de este) no sea un ácido sulfónico; dicha formulación es particularmente adecuada para la administración intravenosa o parenteral a un paciente.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681722P | 2018-06-07 | 2018-06-07 | |
| US201862754651P | 2018-11-02 | 2018-11-02 | |
| US201962796133P | 2019-01-24 | 2019-01-24 | |
| US201962841882P | 2019-05-02 | 2019-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012527A true MX2023012527A (es) | 2023-10-31 |
Family
ID=67402968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013238A MX2020013238A (es) | 2018-06-07 | 2019-06-04 | Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea. |
| MX2023012527A MX2023012527A (es) | 2018-06-07 | 2020-12-04 | Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013238A MX2020013238A (es) | 2018-06-07 | 2019-06-04 | Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US12109308B2 (es) |
| EP (2) | EP3810089B1 (es) |
| JP (2) | JP7423200B2 (es) |
| KR (2) | KR102583563B1 (es) |
| CN (2) | CN112218618A (es) |
| AU (2) | AU2019283550B2 (es) |
| BR (1) | BR112020023891A2 (es) |
| CA (1) | CA3102527A1 (es) |
| DK (1) | DK3810089T3 (es) |
| ES (1) | ES2956225T3 (es) |
| FI (1) | FI3810089T3 (es) |
| HR (1) | HRP20231337T1 (es) |
| HU (1) | HUE063493T2 (es) |
| IL (1) | IL279270A (es) |
| LT (1) | LT3810089T (es) |
| MX (2) | MX2020013238A (es) |
| NZ (1) | NZ770000A (es) |
| PL (1) | PL3810089T3 (es) |
| PT (1) | PT3810089T (es) |
| RS (1) | RS64692B1 (es) |
| SG (1) | SG11202011256RA (es) |
| SI (1) | SI3810089T1 (es) |
| TW (1) | TWI696469B (es) |
| WO (1) | WO2019234632A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20211985T1 (hr) | 2017-08-25 | 2022-04-01 | Pfizer Inc. | Farmaceutska vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu |
| US20230022525A1 (en) | 2021-07-26 | 2023-01-26 | Celcuity Inc. | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
| WO2003015828A1 (en) * | 2001-08-20 | 2003-02-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin |
| US20070111965A1 (en) * | 2005-11-15 | 2007-05-17 | Kipp James E | Compositions comprising lipoxygenase inhibitors and cyclodextrin |
| US10022381B2 (en) | 2008-05-23 | 2018-07-17 | Pfizer Inc. | Triazine compounds as PI3 kinase and mTOR inhibitors |
| ES2728163T3 (es) | 2008-05-23 | 2019-10-22 | Wyeth Llc | Compuestos de triazina como inhibidores de PI3 cinasa y mTOR |
| WO2010096619A1 (en) | 2009-02-23 | 2010-08-26 | Wyeth Llc | Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
| WO2014121235A2 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| PL3116547T3 (pl) | 2014-03-14 | 2019-11-29 | Pfizer | Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania |
| CN107205923B (zh) * | 2014-12-17 | 2021-03-05 | 辉瑞大药厂 | 用于静脉内给药的pi3k/mtor-抑制剂的制剂 |
| KR101829705B1 (ko) * | 2016-09-21 | 2018-02-19 | 씨제이헬스케어 주식회사 | 안정성이 향상된 주사용 조성물 |
| HRP20211985T1 (hr) * | 2017-08-25 | 2022-04-01 | Pfizer Inc. | Farmaceutska vodena formulacija koja sadrži 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]ureu |
-
2019
- 2019-06-04 EP EP19742898.0A patent/EP3810089B1/en active Active
- 2019-06-04 PL PL19742898.0T patent/PL3810089T3/pl unknown
- 2019-06-04 NZ NZ770000A patent/NZ770000A/en unknown
- 2019-06-04 CN CN201980037499.4A patent/CN112218618A/zh active Pending
- 2019-06-04 SI SI201930595T patent/SI3810089T1/sl unknown
- 2019-06-04 ES ES19742898T patent/ES2956225T3/es active Active
- 2019-06-04 KR KR1020207037914A patent/KR102583563B1/ko active IP Right Grant
- 2019-06-04 AU AU2019283550A patent/AU2019283550B2/en active Active
- 2019-06-04 LT LTEPPCT/IB2019/054643T patent/LT3810089T/lt unknown
- 2019-06-04 EP EP23176968.8A patent/EP4249069A3/en active Pending
- 2019-06-04 FI FIEP19742898.0T patent/FI3810089T3/fi active
- 2019-06-04 SG SG11202011256RA patent/SG11202011256RA/en unknown
- 2019-06-04 KR KR1020237032620A patent/KR20230142810A/ko active Application Filing
- 2019-06-04 PT PT197428980T patent/PT3810089T/pt unknown
- 2019-06-04 CN CN202310372451.7A patent/CN116270452A/zh active Pending
- 2019-06-04 HU HUE19742898A patent/HUE063493T2/hu unknown
- 2019-06-04 US US15/734,147 patent/US12109308B2/en active Active
- 2019-06-04 HR HRP20231337TT patent/HRP20231337T1/hr unknown
- 2019-06-04 BR BR112020023891-0A patent/BR112020023891A2/pt unknown
- 2019-06-04 CA CA3102527A patent/CA3102527A1/en active Pending
- 2019-06-04 WO PCT/IB2019/054643 patent/WO2019234632A1/en active Application Filing
- 2019-06-04 RS RS20230948A patent/RS64692B1/sr unknown
- 2019-06-04 DK DK19742898.0T patent/DK3810089T3/da active
- 2019-06-04 MX MX2020013238A patent/MX2020013238A/es unknown
- 2019-06-05 JP JP2019105034A patent/JP7423200B2/ja active Active
- 2019-06-06 TW TW108119644A patent/TWI696469B/zh active
-
2020
- 2020-12-04 MX MX2023012527A patent/MX2023012527A/es unknown
- 2020-12-07 IL IL279270A patent/IL279270A/en unknown
-
2022
- 2022-08-03 AU AU2022211854A patent/AU2022211854B2/en active Active
-
2023
- 2023-08-14 JP JP2023132078A patent/JP7559162B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501794A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2023012527A (es) | Formulacion acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin- 1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il )fenil]urea. | |
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2020011652A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2009013835A (es) | Forma de dosis estabilizada de picoplatino. | |
| NZ748771A (en) | Pharmaceutical compositions comprising nitroxyl donors | |
| BR112015022577A2 (pt) | moduladores ship1 e métodos relacionados a esse | |
| CY1124527T1 (el) | Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση | |
| CY1124820T1 (el) | Φαρμακευτικο υδατικο σκευασμα που περιλαμβανει 1-(4-{[4-(διμεθυλαμινο)πιπεριδιν-1-υλ]καρβονυλ}φαινυλ)-3[4-(4,6-διμορφολιν-4-υλ-1,3,5-τριαζιν-2-υλ)φαινυλ]ουρια | |
| MX2018009458A (es) | Derivado de sulfonamida heterociclico y medicina que contiene el mismo. | |
| MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
| JOP20170197B1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| MY196425A (en) | Indazole Compounds For Use In Tendon And/Or Ligament Injuries | |
| BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . | |
| AR115498A1 (es) | Una formulación acuosa farmacéutica | |
| GEP20207144B (en) | Ophthalmic composition comprising a synergistic combination of glycogen and hyaluronic acid or a salt thereof | |
| EA201692531A1 (ru) | Способы лечения инфекций | |
| MX2022003917A (es) | Formulacion para suspension pediatrica. | |
| MX2022005102A (es) | Compuesto triciclico y uso farmaceutico del mismo. | |
| AR122363A1 (es) | Una composición farmacéutica que comprende derivados de ftalazinona | |
| MX2021004511A (es) | Medicamento para el tratamiento y/o mejora de la septicemia asociada con la anomalia de la coagulacion. | |
| BR112018015979A2 (pt) | composições farmacêuticas e métodos para combater a cardiotoxicidade induzida por quimioterapia | |
| TH1701007409A (th) | สารประกอบเบนซ์ออกซะเซพินออกซะโซลิดิโนนและวิธีการใช้ | |
| NZ747111A (en) | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |